Janus Company Profile

04:06 EDT 18th March 2018 | BioPortfolio

We offer a broad range of investment options, but our expertise is in growth and risk-managed funds. Some of us are driven by a never-ending search for an information advantage. Others by an unwavering pursuit of a statistical advantage. Together, however, our goal is to deliver strong, long-term results to our shareholders. Learn more about us and how we invest.


P.O. Box 173375
United States of America


Phone: 800.525.3713

News Articles [27 Associated News Articles listed on BioPortfolio]

Mylan (MYL) Stake Boosted by Janus Henderson Group PLC

Janus Henderson Group PLC lifted its holdings in Mylan by 56.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 114,620 shares of the company's ...

Mylan N.V. (MYL) Position Trimmed by Janus Henderson Group PLC

Janus Henderson Group PLC lowered its position in Mylan N.V. by 36.8% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 73,231 shares of the company's stock ...

Global and Chinese Cancer Janus Kinase Inhibitor Industry, 2017 Market Research Report [Report Updated: 20122017] Prices from USD $3000

The 'Global and Chinese Cancer Janus Kinase Inhibitor Industry, 20122022 Market Research Report' is a professional and indepth study on the current state of the global Cancer Janus Kinase Inhibitor in...

Janus Kinase 3 JAK3 Inhibitor Pipeline Insight, 2018 [Report Updated: 14022018] Prices from USD $1250

Janus Kinase 3 JAK3 Inhibitor Pipeline Insight, 2018 report by DelveInsight offers comprehensive insights of the pipeline under development therapeutics scenario and growth prospects across Janus Kin...

Bay Area Bigfoot Biomedical Bags $37M Series B Financing

The round was co-led by funds managed by new investor Janus Henderson Investors.

Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile Janus kinase inhibition

Janssen, Theravance Enter Pan-JAK Inhibitor Pact

To develop TD-1473, an oral, GI pan-Janus kinase (JAK) inhibitor for the treatment of inflammatory bowel disease

This Supreme Court Case Is The Biggest Threat To Organized Labor In Years

Mark Janus doesn’t want to pay fees to the labor union that represents him.

Drugs and Medications [0 Results]


PubMed Articles [82 Associated PubMed Articles listed on BioPortfolio]

Stable Janus superhydrophilic/hydrophobic nickel foam for directional water transport.

Janus superhydrophilic/hydrophobic macroporous nickel foam for directional water transport has been demonstrated via a simple floating strategy. Water can transport from hydrophobic to superhydrophili...

Curvature-mediated assembly of Janus nanoparticles on membrane vesicles.

Besides direct particle-particle interactions, nanoparticles adsorbed to biomembranes experience indirect interactions that are mediated by the membrane curvature arising from particle adsorption. In ...

Electrospun Hydrophilic Janus Nanocomposites for the Rapid Onset of Therapeutic Action of Helicid.

The oral delivery of active ingredients for the fast onset of therapeutic effects is a well-known method in patients. In this study, a new kind of hydrophilic Janus structural nanocomposites was desig...

Janus Iron Oxides @ Semiconducting Polymer Nanoparticle Tracer for Cell Tracking by Magnetic Particle Imaging.

Iron oxides nanoparticles tailored for magnetic particle imaging (MPI) have been synthesized, and their MPI signal intensity is 3 times of commercial MPI contrast (Ferucarbotran, also called Vivotrax)...

Chronic active Epstein-Barr virus infection as the initial symptom in a Janus kinase 3 deficiency child: Case report and literature review.

With the progress of sequencing technology, an increasing number of atypical primary immunodeficiency (PID) patients have been discovered, including Janus kinase 3 (JAK3) gene deficiency.

Clinical Trials [12 Associated Clinical Trials listed on BioPortfolio]

A Single Center Prospective Randomized Controlled Clinical Study of JANUS Stent in Patients With Coronary Artery Disease

Janus stent is the only marketed drug-eluting stent (DES) without polymer coating as yet in China. The goal of this study is to evaluate the efficacy of JANUS (Tacrolimus eluted stent) i...

This is a Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor in Patients With Multiple Myeloma

The purpose of this study is to determine clinical efficacy and safety of INCB018424, a small molecule Janus kinase (JAK) inhibitor, in patients with refractory or relapsed multiple myelom...

Study of Tofacitinib in Refractory Dermatomyositis

The purpose of this study is to obtain preliminary data regarding the safety and efficacy of Janus kinase (JAK) inhibitor, tofacitinib, in adults with active, treatment-refractory dermatom...

Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who Have Advanced Non-small Cell Lung Cancer

This study will treat patients with advanced NSCLC who have progressed following prior therapy. This is the first time this drug has ever been tested in patients, and so it will help to un...

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Crohn's Disease Who Completed the Studies M14-431 or M14-433

A multicenter study to evaluate the efficacy and safety of maintenance and long-term treatment administration of upadacitinib, an orally administered Janus kinase 1 inhibitor, in adult par...

Companies [3 Associated Companies listed on BioPortfolio]

Janus Pharmaceuticals, Inc

Janus was founded in 2004 by Catalyst Pharma Group Inc. (CPG), a clinical development services company in the United States and aRigen, Inc., a private equity backed bio-medical venture company in Jap...


We offer a broad range of investment options, but our expertise is in growth and risk-managed funds. Some of us are driven by a never-ending search for an information advantage. Others by an unwaverin...

Blum Capital Partners

Blum Capital Partners, which is headquartered in San Francisco, utilizes private equity and strategic block transactions to invest in both public and private companies.A representative sample of our i...

More Information about "Janus" on BioPortfolio

We have published hundreds of Janus news stories on BioPortfolio along with dozens of Janus Clinical Trials and PubMed Articles about Janus for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Janus Companies in our database. You can also find out about relevant Janus Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record